Mednet Logo
HomeNephrology
Nephrology

Nephrology

Clinical discussions on kidney disease management, dialysis, transplantation, and electrolyte disorders.

Recent Discussions

Are there patients with recurrent nephrolithiasis for who you recommend magnesium supplementation to reduce stone risk?

1
1 Answers

Mednet Member
Mednet Member
Nephrology · Medical College of Wisconsin

While magnesium supplementation may be justified on theoretical grounds, I have never used magnesium supplements as a treatment exclusively for kidney stones. I have only ever seen or used magnesium supplementation in stone patients that had concurrent hypomagnesemia.

What is the current recommendation for using thiazide diuretics in patients with calcium oxalate stone disease, given the negative results of the NOSTONE trial?

4 Answers

Mednet Member
Mednet Member
Nephrology · NYU Grossman School of Medicine

This trial will have no effect on my practice. Seven of 10 previous studies of thiazides for stones were positive, as was a meta-analysis. My preference is for the longer-acting drugs indapamide and chlorthalidone; I haven't used HCTZ which is probably a twice-a-day drug, for some years. Note that t...

Do you recommend taking any unique approaches to managing patients with persistent hypertension following bilateral renal artery stenting?

1
1 Answers

Mednet Member
Mednet Member
Nephrology · UAB Medicine

Yes, I will be more aggressive with lipid management, sometimes using PCSK9-INH in addition to a statin, if the cause of the renal artery stenosis was atherosclerotic-related. Also, I typically get yearly ultrasounds to evaluate the patency of the renal artery stents. From a management perspective, ...

What are your next steps when managing patients with suspected Gitelman syndrome for whom genetic testing reveals variants of uncertain significance or novel mutations not well characterized?

2 Answers

Mednet Member
Mednet Member
Nephrology · Rush Medical College

If the patient had a clinical syndrome that fit the Gitelman phenotype I would totally treating as such.

When would you recommend adding peritoneal dialysis to a patient with oxalosis who is already receiving hemodialysis?

1 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

Tang et al., PMID 24776840I have never done this. The amount of oxalate cleared by peritoneal dialysis is a very small fraction of the amount cleared by hemodialysis. In general, among patients with oxalosis, the oxalate is well cleared from the blood on hemodialysis, but oxalate has a very large vo...

Would you recommend AV fistula placement in a CKD Stage 5 patient who is over the age of 80?

2 Answers

Mednet Member
Mednet Member
Nephrology · Jersey Shore University Medical Center

Depends. If this is an active 80-year-old, then creating a distal fistula (radial-cephalic, when vessels are available) would be ideal compared to a catheter. For someone with limited life expectancy, an alternative (graft or catheter) may be acceptable.

How has the introduction of lumasiran affected the need for combined liver and kidney transplantation in patients with ESKD related to primary hyperoxaluria type 1?

2 Answers

Mednet Member
Mednet Member
Nephrology · University of Alabama Birmingham

A kidney transplant alone with lumasiran pre and post-transplant to maintain lowered serum oxalate levels and prevent the recurrence of oxalate stones is potentially a viable option for simultaneous liver-kidney transplantation.To date, there is only one small case series published of this approach ...

Do you stop tolvaptan below a certain eGFR in a patient with autosomal dominant polycystic kidney disease?

1 Answers

Mednet Member
Mednet Member
Nephrology · UCSF

In general, the practical guidelines support continuing tolvaptan until dialysis or transplant (Chebib and Torres, PMID 33705818). There are situations where I will discontinue sooner, either due to apparent lack of benefit, due to precipitous, unexpectedly rapid decline or accelerated decline, or, ...

Are there other therapies such as SGLT2 inhibitors or alpha lipoic acid that you are offering your patients with cystinuria who continue to have active stone disease despite conservative therapy and thiol-based agents?

1 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

I am not aware of quality trials for new agents being advocated for the treatment of cystinuria. I do not prescribe them. Generally, the failure to respond to standard therapy reflects a failure of the patient to follow the appropriate diet and titrate the usual medications as regards urine pH and c...

Would you consider using finerenone for proteinuric CKD associated with type 1 diabetes mellitus?

1
3 Answers

Mednet Member
Mednet Member
Nephrology · IU Health

Yes, although T1DM is off-label for finerenone and there may be issues regarding its approval by prescription drug plans. I would start with an ACEi/ARB for proteinuria in a T1DM patient, then add spironolactone. If the patient develops breast problems on spironolactone, I would switch to eplerenone...